References
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood [Internet]. 2017;129:424–447. Available from: https://ashpublications.org/blood/article/129/4/424/36196/Diagnosis-and-management-of-AML-in-adults-2017-ELN
- Medeiros BC, Chan SM, Daver NG, et al. Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia. Am J Hematol [Internet]. 2019;94:803–811. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/ajh.25484
- Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol [Internet]. 2019;12:100.Available from: https://jhoonline.biomedcentral.com/articles/https://doi.org/10.1186/s13045-019-0774-x
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med [Internet]. 2020;383:617–629. Available from: http://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2012971
- Lachowiez C, Konopleva M, Kadia TM, et al. Interim analysis of the phase 1b/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed/refractory AML. Blood [Internet]. 2020;136:18–20. Available from: https://ashpublications.org/blood/article/136/Supplement1/18/469978/Interim-Analysis-of-the-Phase-1b-2-Study-of-the
- Megías-Vericat JE, Ballesta-López O, Barragán E, et al. Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control? Blood Rev [Internet]. 2020;44:100675. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0268960X20300254
- Wellbrock J, Latuske E, Köhler J, et al. Expression of hedgehog pathway mediator gli represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects. Clin Cancer Res [Internet]. 2015;21:2388–2398. Available from: http://clincancerres.aacrjournals.org/lookup/doi/https://doi.org/10.1158/1078-0432.CCR-14-1059
- Latuske E-M, Stamm H, Klokow M, et al. Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. Oncotarget [Internet]. 2017;8:29187–29201. Available from: https://www.oncotarget.com/lookup/doi/https://doi.org/10.18632/oncotarget.16304
- Pession A, Lonetti A, Bertuccio S, et al. Targeting Hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities. Expert Opin Ther Targets [Internet]. 2019;23:87–91. DOI:https://doi.org/10.1080/14728222.2019.1559822
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;n71. Available from: https://www.bmj.com/lookup/doi/https://doi.org/10.1136/bmj.n71
- Lewis J, Robinson NJ, Pandya B, et al. Frequency of FLT3-ITD and FLT3-TKD mutations in patients with acute myeloid leukemia: a systematic literature review and meta-analysis. 26th Congress EHA; 2021. p. PB1405.
- Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia [Internet]. 2019 [cited 2019 Nov 6]. 299–312. Available from http://www.ncbi.nlm.nih.gov/pubmed/30651634
- Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther [Internet]. 2017;16:991–1001. Available from: http://mct.aacrjournals.org/lookup/doi/https://doi.org/10.1158/1535-7163.MCT-16-0876
- Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia [Internet]. 2012;26:2061–2068. DOI:https://doi.org/10.1038/leu.2012.115
- Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–464.
- Larson RA, Mandrekar SJ, Sanford BL, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutati. Blood [Internet]. 2017;130. Available from: http://www.bloodjournal.org/content/130/Suppl_1/145%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed18&NEWS=N&AN=620311026
- Azzi J, Cirrone F, Abdul Hay M, et al. Midostaurin in combination with idarubicin and cytarabine (3+7) induction for FLT3 positive AML - very high complete response rates and transition to allogeneic transplantation. Blood. 2018;132:5216.
- Perl AE, Sweet KL, Roboz GJ, et al. Midostaurin in adults with newly diagnosed FLT3-mutation-positive acute myeloid leukemia eligible for standard chemotherapy: update from the radius-X midostaurin expanded access program. Blood. 2018;132:4038.
- Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133:840–851.
- Berger T, Rozovski U, Moshe Y, et al. Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission—a multi-center historical control study. Ann Hematol. 2019;98:2711–2717.
- Voso MT, Larson RA, Jones D, et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv [Internet]. 2020;4:4945–4954. Available from: https://ashpublications.org/bloodadvances/article/4/19/4945/464332/Midostaurin-in-patients-with-acute-myeloid
- Larson RA, Mandrekar SJ, Huebner LJ, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the alliance CALGB 10603/RATIFY trial. Leukemia [Internet]. 2021; Available from: http://www.nature.com/articles/s41375-021-01179-4
- Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant [Internet]. 2021;56:1180–1189. DOI:https://doi.org/10.1038/s41409-020-01153-1
- Maziarz RT, Patnaik MM, Scott BL, et al. Radius: a phase 2, randomized trial of standard of care (SOC) with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients (pts) with FLT3-Itd-mutated acute myeloid leukemia (AML). Blood. 2016;128:2248.
- Maziarz RTT, Patnaik MM, Scott BL, et al. Radius: a phase 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML. Blood. 2018;132:662.
- Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3–internal tandem duplication status. J Clin Oncol [Internet]. 2013 [cited 2019 May 12];31:3681–3687. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24002496
- Cooper TM, Cassar J, Eckroth E, et al. A phase i study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia & lymphoma (TACL) study. Clin Cancer Res. 2016;22:4014–4022.
- Levis MJ, Cortes JE, Gammon GM, et al. Laboratory and clinical investigations to identify the optimal dosing strategy for quizartinib (AC220) monotherapy in FLT3-Itd-positive (+) relapsed/refractory (R/R) acute myeloid leukemia (AML). Blood. 2016;128:4042.
- Swaminathan M, Kantarjian HM, Daver N, et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2017;130:723.
- Cortes JE, Tallman MS, Schiller GJ, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML. Blood [Internet]. 2018;132:598–607. Available from: https://ashpublications.org/blood/article/132/6/598/39411/Phase-2b-study-of-2-dosing-regimens-of-quizartinib
- Cortes J, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19:889–903.
- Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol [Internet]. 2019 [cited 2019 Nov 19];20: 984–997. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204519301500
- Cortes JE, Khaled S, Martinelli G, et al. Quizartinib in FLT3-ITD-mutated relapsed/refractory acute myeloid leukemia: QuANTUM-R trial results. Ann Oncol [Internet]. 2019;30:vi81. DOI:https://doi.org/10.1093/annonc/mdz374.003
- Canaani J, Rea B, Sargent R, et al. Differentiation response to gilteritinib (ASP2215) in relapsed/refractory FLT3 mutated acute myeloid leukemia patients is associated with co-mutations in NPM1 and DNMT3A. Haematologica [Internet]. 2016;101 :42.Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894295/pdf/haematol_2016_s1.pdf%0Ahttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=615550200%0Ahttps://www.cochranelibrary.com/central/doi/https://doi.org/10.1002/central/CN-01362863/full
- Perl AE, Altman JK, Cortes JE, et al. Final results of the chrysalis trial: a first-in-human phase 1/2 dose-escalation, dose-expansion study of gilteritinib (ASP2215) in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Blood. 2016;128:1069.
- Levis MJ, Perl AE, Altman JK, et al. Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leuke. Blood [Internet]. 2018;132:1458–1458. Available from: https://ashpublications.org/blood/article/132/Supplement 1/1458/272921/Impact-of-Minimal-Residual-Disease-and-Achievement.
- Wang J, Li J, Tantiworawit A, et al. A phase III randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia. Ann Oncol. 2018;29:ix92.
- Usuki K, Sakura T, Kobayashi Y, et al. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: an open-label phase 1 study. Cancer Sci. 2018;109:3235–3244.
- Perl AE, Martinelli G, Cortes JE, et al. Abstract CT184: gilteritinib significantly prolongs overall survival in patients with FLT3 -mutated (FLT3 mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial. Clin Trials [Internet]. American Association for Cancer Research; 2019. p. CT184–CT184. Available from: http://cancerres.aacrjournals.org/lookup/doi/https://doi.org/10.1158/1538-7445.AM2019-CT184.
- Cooper BW, Kindwall-Keller TL, Craig MD, et al. A phase i study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk [Internet]. 2015;15:428–432.e2. DOI:https://doi.org/10.1016/j.clml.2015.02.017
- Stone RM, Mandrekar SJ, Sanford BL, et al. The Addition of Midostaurin to standard chemotherapy Decreases cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/ RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Le. Blood. 2017;130:2580.
- Lin T, Mannis GN, Erba HP, et al. V-FAST: a phase 1b master trial to investigate CPX-351 combined with various targeted agents in patients with previously untreated acute myeloid leukemia. Blood [Internet]. 2020;136:26–28. Available from: https://ashpublications.org/blood/article/136/Supplement1/26/470672/V-FAST-A-Phase-1b-Master-Trial-to-Investigate-CPX
- Megías-Vericat JE, Solana-Altabella A, Ballesta-López O, et al. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol [Internet]. 2020;99:1989–2007. Available from: http://link.springer.com/https://doi.org/10.1007/s00277-020-04186-0.
- Perl AE, Cortes JE, Strickland SA, et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol [Internet]. 2017;35:TPS7067TPS7067. Available from: :TPS7067TPS7067. Available from: http://ascopubs.org/doi/https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS7067
- Zhu R, Li L, Nguyen B, et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther [Internet]. 2021;6:186.Available from: http://www.nature.com/articles/s41392-021-00578-4
- Daver N, Wei AH, Pollyea DA, et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J [Internet]. 2020;10:107.Available from: http://www.nature.com/articles/s41408-020-00376-1
- Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood [Internet]. 2005;105:54–60. Available from: https://ashpublications.org/blood/article/105/1/54/19995/Patients-with-acute-myeloid-leukemia-and-an
- Fischer T, Stone RM, DeAngelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28:4339–4345.
- Williams CB, Kambhampati S, Fiskus W, et al. Preclinical and phase i results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy. 2013;33:1341–1352.
- Ramsingh G, Westervelt P, McBride A, et al. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol. 2014;99:272–278.
- Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90:276–281.
- Walker AR, Wang H, Walsh K, et al. Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2016;57:2100–2108.
- Ng C-H, Koh LP, Ooi M, et al. Single institution phase 1 study on combination therapy of midostaurin and panobinostat in acute myeloid leukemia - the interim report. Blood [Internet]. 2018;132:5237. Available from: https://ashpublications.org/blood/article/132/Supplement1/5237/265760/Single-Institution-Phase-1-Study-on-Combination
- Zwaan CM, Söderhäll S, Brethon B, et al. A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia. Br J Haematol [Internet]. 2019;185:623–627. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1111/bjh.15593
- Altman JK, Foran JM, Pratz KW, et al. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93:213–221.
- Yilmaz M, Kantarjian HM, Muftuoglu M, et al. Quizartinib with decitabine ± venetoclax is highly active in patients (Pts) with FLT3 -ITD mutated (mut) acute myeloid leukemia (AML): clinical report and signaling cytof profiling from a phase IB/II trial. Blood [Internet]. 2020;136:19–20. Available from: https://ashpublications.org/blood/article/136/Supplement1/19/470009/Quizartinib-with-Decitabine-Venetoclax-Is-Highly
- Sandmaier BM, Khaled S, Oran B, et al. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93:222–231.
- Pratz KW, Cherry M, Altman JK, et al. Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood [Internet]. 2018;132:564. Available from: https://ashpublications.org/blood/article/132/Supplement1/564/263255/Updated-Results-from-a-Phase-1-Study-of
- Pratz K, Cherry M, Altman JK, et al. Preliminary results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood [Internet]. 2017;130:722. Available from: https://ashpublications.org/blood/article/130/Suppl_1/722/83413/Preliminary-Results-from-a-Phase-1-Study-of
- Esteve J, Schots R, Bernal Del Castillo T, et al. Multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy: findings from the S. Blood [Internet]. 2018;132:2736. Available from: https://ashpublications.org/blood/article/132/Supplement1/2736/264401/Multicenter-OpenLabel-3Arm-Study-of-Gilteritinib
- Yilmaz M, Ravandi F, Loghavi S, et al. Triple combination of HMA, venetoclax, and FLT3 inhibitor produces higher FLT3 PCR clearance, flow MRD negativity, and improved median OS compared with doublets of HMA with FLT3 inhibitor. Haematol conference 24th Congress of the European Hematology Association; 2021. p. EP464.
- Maiti A, DiNardo CD, Ravandi F, et al. Venetoclax, FLT3 inhibitor and decitabine in FLT3 mut acute myeloid leukemia: subgroup analysis of a phase II trial. Blood [Internet]. 2020;136:53–55. Available from: https://ashpublications.org/blood/article/136/Supplement1/53/471718/Venetoclax-FLT3-Inhibitor-and-Decitabine-in
- Maiti A, DiNardo CD, Daver NG, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J [Internet]. 2021;11:4–9. DOI:https://doi.org/10.1038/s41408-021-00410-w
- Wang E, Montesinos P, Minden MD, et al. Gilteritinib plus azacitidine combination shows promise in newly diagnosed FLT3‐mutated AML. Oncologist [Internet]. 2021 [cited 2021 July 28];26. DOI:https://doi.org/10.1002/onco.13652
- Altman J, Daver N, Maly J, et al. Efficacy and safety of venetoclax in combination with gilteritinib for relapsed/refractory FLT3-mutated acute myeloid leukemia: updated analyses of a phase 1b study. Haematol conference 24th Congress of the European Hematology Association; 2021. p. S135.
- Cortes JE, Kantarjian HM, Kadia TM, et al. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. J Clin Oncol. 2016;34:7008.
- Iyer SP, Jethava Y, Karanes C, et al. Safety study of salvage chemotherapy high-dose Ara-C/mitoxantrone (HAM) and type I FLT3-TKI crenolanib in first relapsed/primary refractory AML. Blood [Internet]. 2016;128:3983. Available from: https://ashpublications.org/blood/article/128/22/3983/113782/Safety-Study-of-Salvage-Chemotherapy-HighDose
- Aboudalle I, Kantarjian HM, Ohanian MN, et al. Phase I-II study of crenolanib combined with standard salvage chemotherapy and crenolanib combined with 5-azacitidine in acute myeloid leukemia patients with FLT3 activating mutations. Blood. 2018;132:2715.
- Wang ES, Stone RM, Tallman MS, et al. Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML). Blood. 2016;128:1071.
- Wang ES, Tallman MS, Stone RM, et al. Low relapse rate in younger patients ≤ 60 years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine/anthracycline chemotherapy. Blood [Internet]. 2017;130:566. DOI:https://doi.org/10.1182/blood.V130.Suppl_1.566.566
- Oran B, Ciurea SO, Marin D, et al. Safety analysis of intra-patient dose- study of crenolanib maintenance therapy in patients with FLT3 mutant AML following allogeneic hematopoietic stem cell transplant. Blood. 2018;132:3426.
- Schlenk R, Dombret H, Amadori S, et al. QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML). Je U, Bl S, editors. Ann Oncol [Internet]. 2017;28:v370. Available from: http://link.springer.com/https://doi.org/10.1007/978-1-4899-7305-4
- Cortes JE, Altman J, Ritchie EK, et al. A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction c. J Clin Oncol [Internet]. 2017;35:TPS7068TPS7068. Available from: :TPS7068TPS7068. Available from: http://ascopubs.org/doi/https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS7068
- Levis MJ, Hamadani M, Logan BR, et al. BMT CTN protocol 1506: a phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. Blood [Internet]. 2019;134:4602. Available from: https://ashpublications.org/blood/article/134/Supplement_1/4602/424876/BMT-CTN-Protocol-1506-A-Phase-3-Trial-of
- Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation. Blood [Internet]. 2009;114:5034–5043. Available from: https://ashpublications.org/blood/article/114/24/5034/26614/FLT3ITD-upregulates-MCL1-to-promote-survival-of
- Alvarez JV, Frank DA. Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther [Internet]. 2004;3:1045–1050. Available from: http://www.tandfonline.com/doi/abs/https://doi.org/10.4161/cbt.3.11.1172
- Knapper S, Grech A, Cahalin P, et al. An evaluation of the tyrosine kinase inhibitor pacritinib in patients with relapsed FLT3-mutated acute myeloid leukaemia (the UK NCRI AML17 study). Haematologica [Internet]. 2016;101 (S1):40.Available from: https://library.ehaweb.org/eha/2016/21st/133172/steven.an.evaluation.of.the.tyrosine.kinase.inhibitor.pacritinib.in.patients.html
- Jeon JY, Zhao Q, Buelow DR, et al. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Invest New Drugs. 2020;38:340–349.
- Smith CC, Levis MJ, Frankfurt O, et al. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/ refractory FLT3-ITD–mutant acute myeloid leukemia. Blood Adv. 2020;4:1711–1721.
- Solomon S, Nazha A, Strickland S, et al. Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia. 25th Congr EHA [Internet]. 2020;2020:2017–2018. Available from: https://www.menarini.com/Portals/0/innovazione_e_ricerca/ePosterpublishedonEHAvirtualplatform.pdf
- Solomon SR, Montesinos P, Nazha A, et al. Updated results from DIAMOND-01 (CLI24-001) trial: a phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia. J Clin Oncol [Internet]. 2021;39:7023. Available from: https://meetinglibrary.asco.org/record/195826/abstract
- Levis MJ, Smith CC, Perl AE, et al. Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia. J Clin Oncol [Internet]. 2021;39:7008. Available from: https://meetinglibrary.asco.org/record/195841/abstract
- Ciomei M, Zanetta L, Lussana F, et al. A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML. Blood [Internet]. 2019;134:3855. Available from: https://ashpublications.org/blood/article/134/Supplement_1/3855/424158/A-Phase-III-Study-of-NMS03592088-a-FLT3-KIT-and
- Nam K-Y, Im J, Han -JH-JH-J, et al. PHI-101 is a potent third-generation FLT3 inhibitor developed to overcome resistance in acute myeloid leukemia. Blood. 2020;136:28.
- Daver N, Lee KH, Jung CW, et al. HM43239, a novel small molecule inhibitor of FLT3, in acute myeloid leukemia (AML) with and without FMS-like tyrosine kinase 3 (FLT3) mutations: phase 1/2 study. Blood [Internet]. 2020;136:1. Available from: https://ashpublications.org/blood/article/136/Supplement1/1/470808/HM43239-a-Novel-Small-Molecule-Inhibitor-of-FLT3
- Daver NG, Lee KH, Yoon -S-S, et al. HM43239, a novel potent small molecule FLT3 inhibitor, in acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations: phase 1 /2 study. Blood [Internet]. 2019;134:1331. Available from: https://ashpublications.org/blood/article/134/Supplement_1/1331/427387/HM43239-a-Novel-Potent-Small-Molecule-FLT3
- Eisfelder BJ, Saygin C, Wynne J, et al. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J [Internet]. 2021;11:48.Available from: http://www.nature.com/articles/s41408-021-00433-3
- Smith CC, Zhang C, Lin KC, et al. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 “gatekeeper” F691L mutation with PLX3397. Cancer Discov [Internet]. 2015;5:668–679. Available from: http://cancerdiscovery.aacrjournals.org/lookup/doi/https://doi.org/10.1158/2159-8290.CD-15-0060
- Czardybon W, Windak R, Gołas A, et al. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018;9:16917–16931.
- Yamaura T, Nakatani T, Uda K, et al. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018;131:426–438.
- Yu Z, Du J, Hui H, et al. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. Theranostics. 2020;11:93–106.
- Weisberg E, Meng C, Case AE, et al. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol [Internet]. 2019;187:488–501. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1111/bjh.16092
- Lonetti A, Indio V, Laginestra MA, et al. Inhibition of methyltransferase DOT1L sensitizes to sorafenib treatment AML cells irrespective of MLL-rearrangements: a novel therapeutic strategy for pediatric AML. Cancers (Basel) [Internet]. 2020;12:1972. Available from: https://www.mdpi.com/2072-6694/12/7/1972